Association of a common genetic variant of the IGF-1 gene with event-free survival in patients with HER2-positive breast cancer

Journal of Cancer Research and Clinical Oncology

Volumn 139, Issue 3, 2013, Pages 491-498

  Muendlein, Axel ^a,c   Lang, Alois H ^a,b   Geller Rhomberg, Simone ^a,c   Winder, Thomas ^a,b,c   Gasser, Klaus ^a,b,c   Drexel, Heinz ^a,b,c   Decker, Thomas ^d   Mueller Holzner, Elisabeth ^e   Chamson, Martina ^e   Marth, Christian ^e   Hubalek, Michael ^e  

^a Vorarlberg Institute for Vascular Investigation and Treatment VIVIT   (Austria)

^b Academic Teaching Hospital Feldkirch   (Austria)

^c PRIVATE UNIVERSITY OF THE PRINCIPALITY OF LIECHTENSTEIN   (Liechtenstein)

^d Studienzentrum Onkologie Ravensburg   (Germany)

^e INNSBRUCK MEDICAL UNIVERSITY   (Austria)

Author keywords

Biomarker; Breast cancer; HER2; Insulin like growth factor 1; Single nucleotide polymorphisms

Indexed keywords

ANTINEOPLASTIC AGENT; EPIDERMAL GROWTH FACTOR RECEPTOR 2; GENOMIC DNA; HORMONE; SOMATOMEDIN C;

ADULT; AGE DISTRIBUTION; AGED; ARTICLE; BREAST CANCER; CANCER PATIENT; CANCER PROGNOSIS; CANCER STAGING; CANCER TISSUE; EVENT FREE SURVIVAL; GENETIC ASSOCIATION; GENETIC VARIABILITY; GENOTYPE; HETEROZYGOTE; HUMAN; HUMAN TISSUE; IGF 1 GENE; MAJOR CLINICAL STUDY; OVERALL SURVIVAL; POLYMERASE CHAIN REACTION; PRIORITY JOURNAL; PROTEIN BLOOD LEVEL; SINGLE NUCLEOTIDE POLYMORPHISM; BREAST TUMOR; CARCINOMA; DISEASE FREE SURVIVAL; FEMALE; GENETICS; METABOLISM; MIDDLE AGED; MORTALITY; PHYSIOLOGY; PROGNOSIS; SURVIVAL;

ADULT; AGED; BREAST NEOPLASMS; CARCINOMA; DISEASE-FREE SURVIVAL; FEMALE; GENETIC ASSOCIATION STUDIES; GENOTYPE; HUMANS; INSULIN-LIKE GROWTH FACTOR I; MIDDLE AGED; POLYMORPHISM, SINGLE NUCLEOTIDE; PROGNOSIS; RECEPTOR, ERBB-2; SURVIVAL ANALYSIS;

MLCS; MLOWN;

EID: 84876311827     PISSN: 01715216     EISSN: 14321335     Source Type: Journal    
DOI: 10.1007/s00432-012-1355-3     Document Type: Article

References (38)

1. Al Zahrani A, Sandhu MS, Luben RN, Thompson D, Baynes C, Pooley KA, Luccarini C, Munday H, Perkins B, Smith P, Pharoah PD, Wareham NJ, Easton DF, Ponder BA, Dunning AM (2006) IGF1 and IGFBP3 tagging polymorphisms are associated with circulating levels of IGF1, IGFBP3 and risk of breast cancer. Hum Mol Genet 15:1-10
2. Beech DJ, Parekh N, Pang Y (2001) Insulin-like growth factor-I receptor antagonism results in increased cytotoxicity of breast cancer cells to doxorubicin and taxol. Oncol Rep 8:325-329
3. Bertrand FE, Steelman LS, Chappell WH, Abrams SL, Shelton JG, White ER, Ludwig DL, McCubrey JA (2006) Synergy between an IGF-1R antibody and Raf/MEK/ERK and PI3 K/Akt/mTOR pathway inhibitors in suppressing IGF-1R-mediated growth in hematopoietic cells. Leukemia 20:1254-1260
4. Brokaw J, Katsaros D, Wiley A, Lu L, Su D, Sochirca O, de la Longrais IA, Mayne S, Risch H, Yu H (2007) IGF-I in epithelial ovarian cancer and its role in disease progression. Growth Factors 25:346-354
5. Chen W, Wang S, Tian T, Bai J, Hu Z, Xu Y, Dong J, Chen F, Wang X, Shen H (2009) Phenotypes and genotypes of insulin-like growth factor 1, IGF-binding protein-3 and cancer risk: evidence from 96 studies. Eur J Hum Genet 17(12):1668-1675
6. Deming SL, Ren Z, Wen W, Shu XO, Cai Q, Gao YT, Zheng W (2007) Genetic variation in IGF1, IGF-1R, IGFALS, and IGFBP3 in breast cancer survival among Chinese women: a report from the Shanghai Breast Cancer Study. Breast Cancer Res Treat 104:309-319
7. Dong X, Javle M, Hess KR, Shroff R, Abbruzzese JL, Li D (2010) Insulin-like growth factor axis gene polymorphisms and clinical outcomes in pancreatic cancer. Gastroenterology 139:464-473
8. Dupont WD, Plummer WD Jr (1990) Power and sample size calculations. A review and computer program. Control Clin Trials 11:116-128
9. Eckstein N, Servan K, Hildebrandt B, Politz A, von Jonquieres G, Wolf-Kummeth S, Napierski I, Hamacher A, Kassack MU, Budczies J, Beier M, Dietel M, Royer-Pokora B, Denkert C, Royer HD (2009) Hyperactivation of the insulin-like growth factor receptor I signaling pathway is an essential event for cisplatin resistance of ovarian cancer cells. Cancer Res 69:2996-3003
10. Ferlay J, Shin HR, Bray F, Forman D, Mathers C, Parkin DM (2010) Estimates of worldwide burden of cancer in 2008: GLOBOCAN 2008. Int J Cancer 127:2893-2917
11. Gerger A, El Khoueiry A, Zhang W, Yang D, Singh H, Bohanes P, Ning Y, Winder T, Labonte MJ, Wilson PM, Benhaim L, Paez D, El Khoueiry R, Absenger G, Lenz HJ (2011) Pharmacogenetic angiogenesis profiling for first-line bevacizumab plus oxaliplatin-based chemotherapy in patients with metastatic colorectal cancer. Clin Cancer Res 17:5783-5792
12. Goldhirsch A, Wood WC, Coates AS, Gelber RD, Thürlimann B, Senn HJ (2011) Panel members. Ann Oncol 22:1736-1747
13. Grimberg A (2003) Mechanisms by which IGF-I may promote cancer. Cancer Biol Ther 2:630-635
14. Harrela M, Koistinen H, Kaprio J, Lehtovirta M, Tuomilehto J, Eriksson J, Toivanen L, Koskenvuo M, Leinonen P, Koistinen R, Seppala M (1996) Genetic and environmental components of interindividual variation in circulating levels of IGF-I, IGF-II, IGFBP-1, IGFBP-3. J Clin Invest 98:2612-2615
15. Helzlsouer KJ, Alberg AJ, Rollison DE, Overvad K, Kaaks R, Trichopoulos D, Clavel-Chapelon F et al (2010) Insulin-like growth factor 1 (IGF1), IGF binding protein 3 (IGFBP3), and breast cancer risk: pooled individual data analysis of 17 prospective studies. Lancet Oncol 11:530-542
16. International HapMap Consortium (2005) A haplotype map of the human genome. Nature 437:1299-1320
17. Kahán Z, Gardi J, Nyári T, Földesi I, Hajnal-Papp R, Ormándi K, Lázár G, Thurzó L, Schally AV (2006) Elevated levels of circulating insulin-like growth factor-I, IGF-binding globulin-3 and testosterone predict hormone-dependent breast cancer in postmenopausal women: a case-control study. Int J Oncol 29:193-200
18. Key TJ, Appleby PN, Reeves GK, Roddam AW (2010) Insulin-like growth factor 1 (IGF1), IGF binding protein 3 (IGFBP3), and breast cancer risk: pooled individual data analysis of 17 prospective studies. Lancet Oncol 11:530-542
19. Lang AH, Geller-Rhomberg S, Winder T, Stark N, Gasser K, Hartmann B, Kohler B, Grizelj I, Drexel H, Muendlein A (2012) A common variant of the MACC1 gene is significantly associated with overall survival in colorectal cancer patients. BMC Cancer 12:20
20. Lee PH, Shatkay H (2008) F-SNP: computationally predicted functional SNPs for disease association studies. Nucleic Acids Res 36:D820-D824
21. Lu Y, Zi X, Zhao Y, Mascarenhas D, Pollak M (2001) Insulin-like growth factor-I receptor signaling and resistance to trastuzumab (Herceptin). J Natl Cancer Inst 93:1852-1857
22. Mamay CL, Mingo-Sion AM, Wolf DM, Molina MD, Van Den Berg CL (2003) An inhibitory function for JNK in the regulation of IGF-I signaling in breast cancer. Oncogene 22:602-614
23. Matuoka K, Yu CK (1999) Nuclear factor Y (NF-Y) and cellular senescence. Exp Cell Res 253:365-371
24. Patel AV, Cheng I, Canzian F, Le Marchand L, Thun MJ, Berg CD, Buring J et al (2008) IGF-1, IGFBP-1, and IGFBP-3 polymorphisms predict circulating IGF levels but not breast cancer risk: findings from the Breast and Prostate Cancer Cohort Consortium (BPC3). PLoS One 3:e2578
25. Pollak M (2008) Insulin and insulin-like growth factor signalling in neoplasia. Nat Rev Cancer 8:915-928
26. Raile K, Berthold A, Banning U, Horn F, Pfeiffer G, Kiess W (2003a) IGFs, basic FGF, and glucose modulate proliferation and apoptosis induced by IFNgamma but not by IL-1beta in rat INS-1E beta-cells. Horm Metab Res 35:407-414
27. Raile K, Hille R, Laue S, Schulz A, Pfeifer G, Horn F, Kiess W (2003b) Insulin-like growth factor I (IGF-I) stimulates proliferation but also increases caspase-3 activity, Annexin-V binding, and DNA-fragmentation in human MG63 osteosarcoma cells: co-activation of pro- and anti-apoptotic pathways by IGF-I. Horm Metab Res 35:786-793
28. Rowlands MA, Holly JM, Hamdy F, Phillips J, Goodwin L, Marsden G, Gunnell D, Donovan J, Neal DE, Martin RM (2012) Serum insulin-like growth factors and mortality in localised and advanced clinically detected prostate cancer. Cancer Causes Control 23:347-354
29. Skolnik EY, Batzer A, Li N, Lee CH, Lowenstein E, Mohammadi M, Margolis B, Schlessinger J (1993) The function of GRB2 in linking the insulin receptor to Ras signaling pathways. Science 260:1953-1955
30. Slamon DJ, Clark GM, Wong SG, Levin WJ, Ullrich A, McGuire WL (1987) Human breast cancer: correlation of relapse and survival with amplification of the HER-2/neu oncogene. Science 235:177-182
31. Stattin P, Rinaldi S, Biessy C, Stenman UH, Hallmans G, Kaaks R (2004) High levels of circulating insulin-like growth factor-I increase prostate cancer risk: a prospective study in a population-based nonscreened cohort. J Clin Oncol 22:3104-3112
32. Thissen JP, Ketelslegers JM, Underwood LE (1994) Nutritional regulation of the insulin-like growth factors. Endocr Rev 15:80-101
33. Tsuchiya N, Wang L, Suzuki H, Segawa T, Fukuda H, Narita S, Shimbo M, Kamoto T, Mitsumori K, Ichikawa T, Ogawa O, Nakamura A, Habuchi T (2006) Impact of IGF-I and CYP19 gene polymorphisms on the survival of patients with metastatic prostate cancer. J Clin Oncol 24:1982-1989
34. Valenciano A, Henriquez-Hernandez LA, Moreno M, Lloret M, Lara PC (2012) Role of IGF-1 receptor in radiation response. Transl Oncol 5:1-9
35. Vlachostergios PJ, Gioulbasanis I, Kamposioras K, Georgoulias P, Baracos VE, Ghosh S, Maragouli E, Georgoulias V, Papandreou CN (2011) Baseline insulin-like growth factor-I plasma levels, systemic inflammation, weight loss and clinical outcome in metastatic non-small cell lung cancer patients. Oncology 81:113-118
36. Winder T, Zhang W, Yang D, Ning Y, Bohanes P, Gerger A, Wilson PM, Pohl A, Mauro DJ, Langer C, Rowinsky EK, Lenz HJ (2010) Germline polymorphisms in genes involved in the IGF1 pathway predict efficacy of cetuximab in wild-type KRAS mCRC patients. Clin Cancer Res 16:5591-5602
37. Wong AL, Lee SC (2012) Mechanisms of resistance to Trastuzumab and Novel therapeutic strategies in HER2-positive breast cancer. Int J Breast Cancer 2012:415170
38. Zhang M, Hu Z, Huang J, Shu Y, Dai J, Jin G, Tang R, Dong J, Chen Y, Xu L, Huang X, Shen H (2010) A 3′-untranslated region polymorphism in IGF1 predicts survival of non-small cell lung cancer in a Chinese population. Clin Cancer Res 16:1236-1244